Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Mita on Emergence of Checkpoint Inhibitors SCLC

February 20th 2020

Alain C. Mita, MD, discusses the impact of checkpoint inhibitors on the small cell lung cancer treatment paradigm.

Unpacking IO Innovations in Lung Cancer in Pittsburgh

February 19th 2020

We traveled to Pittsburgh, Pennsylvania, for a State of the Science Summit™ on Lung Cancer, which featured insights from the UPMC and Fox Chase Cancer Center faculty.

Efforts Expand for Targeting Rare Alterations in NSCLC

February 19th 2020

Karen Reckamp, MD, MS, highlights the different agents that have been developed to target rarer abnormalities in non–small cell lung cancer.

FDA Grants Priority Review to Frontline Atezolizumab for Advanced PD-L1-High NSCLC

February 19th 2020

The FDA has granted a priority review designation to a supplemental biologics license application for single-agent atezolizumab as a frontline treatment for patients with advanced nonsquamous or squamous non–small cell lung cancer without EGFR or ALK mutations who have high PD-L1 expression on tumor cells or tumor-infiltrating immune cells, defined as TC3/IC3 wild-type.

Newer ALK+ NSCLC Options Focus on Targeting Acquired Resistance

February 19th 2020

Anne Chiang, MD, PhD, discusses the currently available treatments and ongoing research in ALK-positive non–small cell lung cancer.

Dr. Pennell on Considerations for Immediate Treatment in Lung Cancer

February 19th 2020

Nathan A. Pennell, MD, PhD, discusses the considerations when choosing therapy for patients with lung cancer who need immediate therapy but have not received the results of their molecular testing.

Lynch Settles Into New Role at Fred Hutch

February 18th 2020

Thomas J. Lynch Jr, MD, discusses his journey in the field of oncology, his transition to Fred Hutchinson Cancer Research Center, and his goals for the institution going forward.

FDA Grants Priority Review to Lurbinectedin in Small Cell Lung Cancer

February 17th 2020

The FDA has granted a priority review designation to a new drug application for lurbinectedin as a treatment for patients with small cell lung cancer who have progressed following platinum-containing therapy.

High BMI Linked to Better Immunotherapy Outcomes in NSCLC

February 14th 2020

A high body mass index at baseline may be independently associated with improved survival outcomes in patients with non–small cell lung cancer who receive immune checkpoint inhibitor therapy.

NEJM Data Show Volume CT Screening Lowers Mortality in High-Risk Lung Cancer

February 12th 2020

Patients with high-risk lung cancer who underwent volume CT screening had a significantly lower lung cancer mortality compared with those who were not screened.

FDA Grants Priority Review to Capmatinib in METex14+ NSCLC

February 11th 2020

The FDA has granted a priority review designation to a new drug application for capmatinib for use as treatment for newly diagnosed and previously treated patients with locally advanced or metastatic MET exon14 skipping—mutated non–small cell lung cancer.

Assessing Treatment Strategies ALK+ Lung Cancer

February 11th 2020

Luis E. Raez, MD, provides insight into therapies available to patients with ALK-mutant non–small cell lung cancer and underscores the role of genetic testing in informing treatment decisions.

Dr. Wakelee on Immediate Therapy Options in Lung Cancer

February 10th 2020

Heather A. Wakelee, MD, discusses therapy options when patients with lung cancer must receive treatment options immediately rather than wait for molecular testing results.

Dr. Pennell on Benefits of Liquid Biopsies in Lung Cancer

February 10th 2020

Nathan A. Pennell, MD, PhD, discusses the benefits of liquid biopsies in lung cancer.

FDA Approves Pemetrexed Injection for Nonsquamous NSCLC and Malignant Pleural Mesothelioma

February 10th 2020

The FDA has granted a final approval to pemetrexed for injection, an alternative to standard pemetrexed, for the treatment of patients with locally advanced or metastatic nonsquamous non–small cell lung cancer and for those with malignant pleural mesothelioma.

Brahmer Highlights Next Steps for Osimertinib in EGFR-Mutant NSCLC

February 10th 2020

Julie R. Brahmer, MD, discusses the impact of osimertinib in EGFR-mutant non–small cell lung cancer, ongoing research with the agent, and the importance of molecular testing.

Should EGFR TKI Use Expand in Frontline NSCLC?

February 10th 2020

Treatment with osimertinib in the frontline has been the standard of care for patients with EGFR-mutant non–small cell lung cancer since the pivotal FLAURA trial.

Therapeutic Advances Promote Personalized Medicine in Advanced NSCLC

February 10th 2020

Significant research advances in targeted therapy and immunotherapy within the past years have created a more personalized approach to treatment for patients with advanced non–small cell lung cancer.

Dr. Ramalingam on Treatment Parameters for Osimertinib in Lung Cancer

February 9th 2020

Suresh S. Ramalingam, MD, FASCO, discusses the current treatment parameters for osimertinib in EGFR-mutant non–small cell lung cancer and ongoing research with the agent.

Immunotherapy Restructures the SCLC Treatment Landscape

February 9th 2020

The standard of care for patients with small cell lung cancer has been trapped in a period of stagnation for the past several decades.